Investor Relations

Crinetics Pharmaceuticals (NASDAQ: CRNX): Investor Relations Program

February 28, 2024

LIFESCI ACTIVITIES: Transparency and Communication: LifeSci helped Crinetics to determine appropriate expectations, craft messaging around those expectations, and carry through with them. Investor Education: LifeSci helped create a clear investor targeting strategy that optimized the management team’s time and resources. The strategy required selectivity and prioritization to avoid fatigue, as apposed to adopting an “any…

Read More

Ambrx Biopharma, Inc. (NASDAQ: AMAM): Investor Relations Program

January 8, 2024

BACKGROUND LifeSci embarked on a journey with Ambrx, beginning in November 2022, with a shared vision of enhancing its market presence and investor relations landscape. Over the course of this partnership, LifeSci’s approach was multifaceted, aiming not just to amplify Ambrx’s visibility, but to weave a narrative that resonated deeply with investors and stakeholders alike.…

Read More

Vyne Therapeutics (NASDAQ: VYNE): Investor Relations Program

October 30, 2023

BACKGROUND Vyne Therapeutics engaged LifeSci Advisors in a strategic partnership to elevate its presence among global investors since 2014. LIFESCI’S ACTIVITIES • Thorough market research, including landscape analysis & peer company reviews, was conducted to refine VYNE’s equity narrative. This involved assessing clinical development timelines, data curves, and market opportunities to better align with investor…

Read More

Verrica Pharmaceuticals (NASDAQ:VRCA): Investor Relations Program

July 19, 2023

BACKGROUND Verrica Pharmaceuticals has been a LifeSci client since December 2022. As part of the strategy to raise the Company’s visibility amongst global investors, LifeSci scheduled multiple Non-Deal Roadshows with top-tier institutions as well as organized and hosted an in-person High-Net-Worth and family-office investor event for Verrica in New York City. The event created a…

Read More

Abivax (ENXTPA: ABVX): Investor Relations Program

July 18, 2023

LifeSci has worked extensively with Abivax since 2015 to optimize and improve company positioning to actively increase visibility amongst investors and strategics internationally. With iterative updates to company materials, LifeSci strives to provide in depth updates and reviews of all internal and external content. LIFESCI’s ACTIVITIES Strengthened Abivax’s position globally as a leader in the…

Read More

Amryt Pharma (NASDAQ: AMYT, AMYT.LON): Investor Relations Program

February 14, 2023

LifeSci have worked extensively over the years to raise the Company’s visibility amongst investors and strategics, preparing the market for their positive data read out and ultimately leading to a successful acquisition. LIFESCI’s ACTIVITIES Strengthen Amryt’s position as a global leader in rare and orphan diseases through strategic corporate communications following the acquisition of Chiasma…

Read More

CinCor Pharma (NASDAQ: CINC): Investor Relations Program

January 9, 2023

BACKGROUND: At the request of the CFO, LifeSci Advisors started working with CinCor a few months prior to their $200M IPO on Jan 6th, 2022. LIFESCI’s ACTIVITIES Pre-IPO:  LifeSci performed the following activities which brought investors into the stock and ultimately led to a successful equity offering: Advised on messaging and changes to investor presentation…

Read More

Bellus Health (NASDAQ: BLU) Investor Relations Program

October 19, 2022

BACKGROUND Bellus Health is a clinical-stage biopharmaceutical company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of refractory chronic cough. LifeSci Advisors has been engaged to support Bellus Health with investor…

Read More

PharmaMar (PHM.BME): Investor Relations Program

June 7, 2022

Background PharmaMar is a commercial-stage oncology company headquartered in Spain and listed on the Bolsas y Mercados Españoles exchange. Despite the successful commercial launch of PharmaMar’s product Zepzelca® (lurbinectedin) in 2020 by partner Jazz Pharmaceuticals as a second-line treatment for SCLC, the Zepzelca® story struggled to gain traction with investors and the broader PharmaMar investment…

Read More

Valneva Investor Relations Program

May 20, 2022

In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of promising COVID-19, Lyme Disease, and Chikungunya vaccines. LifeSci worked to raise Valneva’s visibility among the investment community and position Valneva for a successful US dual-listing and global equity offering.  …

Read More